Newsroom & Press Releases

VisionGate, Inc. Appoints R. John Glasspool as Chief Operating and Strategy Officer and member of the Board of Directors
Press Release, October 11, 2018

VisionGate Announces the Results and Presentation of Important New Research at the 2018 IASLC World Conference on Lung Cancer (WCLC), Toronto, Canada.
Press Release, September 24, 2018

VisionGate Announces New Appointment to the Board of Directors
Press Release, June 14, 2018

VisionGate, Inc. Appoints Randal Buness as Chief Financial Officer
Press Release, April 17, 2018

VisionGate’s Cell-CT™ 3D Cellular Imaging Platform Detects the Presence of Cancer-Associated Cells (CACs) that have undergone Malignancy Associated Change (MAC)
Press Release, April 16, 2018

VisionGate Lung Cancer 3D Cellular Imaging Research to be Featured as a Late-Breaking Abstract at the AACR Annual Meeting 2018
Press Release, April 12, 2018

VisionGate is Leveraging the Cell-CT™ Platform to Expand Cancer Diagnostics Services, Biopharmaceutical Services and Cancer Prevention Medicines
Press Release, April 5, 2018

VisionGate Announces Two New Appointments to the Board of Directors; Biotech Experienced Directors Further Strengthen the Company Leadership
Press Release, April 4, 2018

New Research Study Demonstrates Applicability of VisionGate’s 3-Dimensional Cell-CT™ Imaging and Analysis Platform
Press Release, December 12, 2017

VisionGate® Showcases Advances in Lung Cancer Early Detection and Treatment at the World Conference on Lung Cancer
Press Release, October 19, 2017

VisionGate Hires Prominent Pathologist as Medical Director, VisionGate, Inc.
Press Release, June 7, 2017

17th World Conference on Lung Cancer: VisionGate Will Speak Twice! November 2016

VisionGate to Speak for The Exclusive Piper Jaffray Conference at The Lotte New York Palace Hotel November 2016

Ahwatukee bio-tech company focusing on cure for lung cancerAhwatukee Foothills News, November 2016

Arizona-based Trinnovate Ventures invests in 4 start-upsArizona Business Magazine, October 2016

Tiny Channels, Giant DreamsCancer Cytopathology, July 2016

VisionGate Hires Renowned Chief Medical Officer Dr. Javier Zulueta June 2016

VisionGate’s LuCED® Test and New Drug Therapy to Prevent Lung Cancer Demonstrate Promise in National Surveys of Pulmonologists June 2016

VisionGate’s LuCED Test and New Drug Therapy to Prevent Lung Cancer Demonstrate Promise in National Surveys of PulmonologistsAZBio, June 2016

VisionGate’s Alan Nelson Named Academy of Inventors Fellow April 2016

Trinnovate Invests Heavily in VisionGate’s Lung Cancer Clinical TrialsLung Disease News, March 2016

Meet the Finalists for Healthcare Leadership Awards Arizona Business Magazine, March 2016

VisionGate Receives Strategic Investment from Trinnovate VenturesBioPortfolio, March 2016

VisonGate Receives Strategic Investment from Trinnovate Ventures March 2016

Biotech Showcase 2016 Interview: Diagnostics company VisionGate migrates into therapeutics –  EBD Group, February 2016

VisionGate to Present at Leerink Partners Global Healthcare Conference February 2016

Lung Cancer Pioneers Create Lung Cancer Eradication Pact: VisionGate Acquires Exclusive Rights to University of Colorado’s Chemoprevention Drug Iloprost February 2016

Rights to Patent for Lung Cancer Prevention Drug Iloprost Acquired by VisionGateLung Disease News, January 2016

Phoenix biotech firm expands portfolio with new treatment to prevent lung cancerPhoenix Business Journal, January 20161

Related Pages

This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.

Copyright 2018 - VisionGate, Inc.